NEW AT AD/PDTM 2017 – FORUM DISCUSSIONS
These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in "hottest" research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer's and Parkinson's therapeutics.
Each forum will be 120 minutes moderated discussion with maximum 3 minutes introduction statement from each participant followed by selected questions from the audience submitted through the Ask the Speaker function in the mibile APP, prioritized and introduced to the discussion by the moderator. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.
AD/PDTM 2017 ALZHEIMER CLINICAL PHASE 3 FORUM: THE RACE FOR THE FIRST DISEASE MODIFYING DRUG FOR AD: FACTORS FOR SUCCESS
Saturday, April 1; 14:45-16:45: HALL A
Moderator: John C Morris, Washington University School of Medicine in St. Louis, USA
Larry Altstiel, Executive VP and Chief Medical Officer, vTv Therapeutics LLC, USA: NEW SCIENCE, RIGOROUS DEVELOPMENT: A NEED FOR BOTH NOVEL APPROACHES TO AD PATHOLOGY AND A RETURN TO ORDERLY, DATA-DRIVEN CLINICAL RESEARCH
Samantha Budd-Haeberlain, VP Alzheimer's Discovery & Development, Biogen, USA: THE
IMPORTANCE OF EARLY IDENTIFICATION AND TREATMENT OF ALZHEIMER'S DISEASE
Paulo Fontoura, Vice President, Global Head Clinical Development Neuroscience, Roche, Switzerland: ADVANCING THE SCIENCE OF AD DRUG DEVELOPMENT – TOWARD 2025 AND BEYOND
David Michelson, Vice President, Clinical Neuroscience and Ophthalmology, Merck, USA
Andrew Satlin, Executive Vice-President, Eisai, USA: BACK TO BASICS: THE NEED FOR PHASE 2 PROOF-OF-CONCEPT FOR CLINICAL EFFECT IN AD DRUG DEVELOPMENT
John Sims, Senior Medical Director, Eli Lilly, USA: THE SCIENTIFIC METHOD OF FAILURE
Johannes Streffer, Senior Director, Neuroscience Clinical Development, Janssen Research & Development, Belgium
Terry Fullerton, Senior Director, Neuroscience and Pain, Global Product Development, Pfizer, USA: IMPROVING
DECISION MAKING IN AD CLINICAL DEVELOPMENT
AD/PDTM 2017 ALZHEIMER ANIMAL MODEL FORUM: PRECLINICAL PREDICTIVE DRUG TESTING: THE STORY OF MICE, RATS, DOGS, NON HUMAN PRIMATES AND MEN
Wednesday, March 29; 14:0-16:00: HALL A
Moderator: Manfred Windisch, CEO and President, NeuroScios GmbH, Austria
Joseph Araujo, President and CEO, Intervivo, CANADA: HOW CLOSELY DO AGED DOGS MODEL HUMAN AD? ARE THEY A PREDICTIVE DISEASE MODEL?
Robert M. Cohen, Emory University Hospital, USA: GENETIC MANIPULATION AND AGING IN THE FISCHER 344 RAT: APPROACHING HUMAN AD IN A RODENT MODEL
Frank LaFerla, University of California Irvine, USA: THE HUMANIZED MOUSE MODELS OF AD" A NEW TREND, BUT ARE THESE MICE REALLY SHOWING ADVANTAGE TO CONVENTIONAL GENETICALLY MODIFIED MICE?
Emer Leahy, President & CEO, Psychogenics Inc., USA: THE NEXT GENERATION OF BEHAVIOURAL TESTING USING ADVANCED COMPUTER-TECHNOLOGY, ROBOTICS AND BIOINFORMATICS IN COMBINATION WITH WELL VALIDATED MODELS AS A BASIS FOR PREDICTIVE VALIDITY
Mu-Ming Poo, University of California Berkley, USA: WHY DO WE NEED NON-HUMAN PRIMATE MODELS FOR DEVELOPING TREATMENTS FOR AD IN THE FUTURE?
AD/PDTM 2017 FORUM ON TRANSLATIONAL RESEARCH IN DRUG DISCOVERY FOR AD: A PLETHORA OF TARGETS: WHICH IS THE BEST, IS THERE "A BEST ONE"?
Thursday, March 30; 14:45-16:45: HALL A
Moderator: Ezio Giacobini, University of Geneva Medical School Hospitals, Switzerland and Bengt Winblad, Karolinska Institute, Sweden
Susan Catalano, Founder & CSO, Cognition Therapeutics Inc, USA: DIRECT DISPLACEMENT OF Aβ OLIGOMERS FOR EFFFECTIVE ALZHEIMER'S DIEASE MODIFICATION: CLINICAL EXPERIENCE WITH CT1812
Teiji Kimura, Chief Discovery Officer, Eisai, Japan: COMBINATION THERAPY ERA WILL EMERGE FOR ALZHEIMER'S DISEASE MODIFICATION IN NEAR FUTURE. CAN BIOMARKERS SUGGEST THE BEST OPTION TO HETEROGENEOUS PATIENTS?
Martin Tolar, Founder, President & CEO, Alzheon, USA: ALZ-801: EFFICIENT ALZHEIMER'S DISEASE MODIFICATION BY PREVENTING FORMATION OF TOXIC AMYLOID AGGREGATES
David Elmaleh, Scientific Founder and Chairman, AZ Therapeutics, USA
Lon S. Schneider, Keck School of Medicine of the University of Southern California, USA: A PLETHORA OF BEST TARGETS OR WINNERS' CURSES? UNTURNED STONES AND WHY TRIALS FAIL
Bengt Winblad, Karolinska Institute, Sweden: WHAT IS THE DRIVING FORCE BEHIND CLINICAL TRIALS JUMPING OVER PHASE II;INCREASED
RISK FOR FAILED PHASE III?
AD/PDTM 2017 FORUM ON NOVEL APPROACHES TO DISEASE-MODIFYING THERAPIES OF PD: THERAPY OF PD BEYOND NEUROTRANSMITTER REPLACEMENT. CAN WE STOP PROGRESSION?
Friday, March 31; 14:45-16:45: HALL A
Moderator: Jamie Eberling,Director, Research Programs,Michael J Fox Foundation, USA
Jesse Cedarbaum, Vice
President, Parkinson's and Movement Disorders Research and Early Development,
Biogen, USA: DISEASE
MODIFICATION IN PD: WILL WE KNOW IT WHEN WE SEE IT?
James Galvin, NIA Lewy Body Initiative, USA
Peter Lansbury, Chief Scientific Officer, Lysosomal Therapeutics, Inc, USA: DEVELOPMENT
OF AN ALLOSTERIC GLUCOCEREBROSIDASE ACTIVATOR FOR GBA-PD
Walter Koroshetz, Director, NINDS, USA: CAN
PROGRESSION IN PARKINSON’S PATIENTS BE STOPPED WITHOUT STOPPING INITIATION?
Eliezer Masliah, Director of the Division of Neuroscience at the National Institute on Aging (NIA), USA
Jose Obeso, Editor, Movement Disorders Journal, Spain: FUNCTIONAL RESTORATION OF ABNORMAL CIRCUITS CAN BE DISEASE MODIFYING IN PARKINSON DISEASE
Gene Kinney, President and Chief Executive Officer, Prothena, USA:THE DEVELOPMENT OF
ALPHA-SYNUCLEIN TARGETING MONOCLONAL ANTIBODIES TO
SLOW DISEASE PROGRESSION
Fabrizio Stocchi, Institute for Research and Medical Care San Raffaele, Italy